XML 46 R12.htm IDEA: XBRL DOCUMENT
v3.26.1

BALANCE SHEET COMPONENTS | 12 Months Ended
--- | ---
Dec. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
BALANCE SHEET COMPONENTS | 5. BALANCE SHEET COMPONENTS Inventory Inventory comprised the following amounts:
| December 31, 2025 |  | December 31, 2024
Finished goods | $ | 107 |  |  | $ | 176 |
Work in process | 994 |  |  | 897 |
Raw materials | 1,886 |  |  | 1,556 |
Inventory | $ | 2,987 |  |  | $ | 2,629 |
For the years ended December 31, 2025 and December 31, 2024, there were no provisions to write down inventories. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets comprised the following amounts:
| December 31, 2025 |  | December 31, 2024
Prepayment for insurance | $ | 324 |  |  | $ | 64 |
Advance payments for inventory purchases | $ | 300 |  |  | $ | 349 |
Deferred initial public offering costs | — |  |  | 225 |
Other | 448 |  |  | 260 |
Prepaid expenses and other current assets | $ | 1,072 |  |  | $ | 898 |
Deferred initial public offering costs are specific incremental costs directly attributable to an initial public offering of equity securities that were reclassified from current assets to stockholders' equity and recorded as reductions to the gross proceeds from the offering. Property and Equipment, Net Property and equipment comprised the following amounts:
| December 31, 2025 |  | December 31, 2024
Machinery and equipment | $ | 928 |  |  | $ | 821 |
Computer equipment, office equipment, and purchased software | 101 |  |  | 101 |
Leasehold improvements | 157 |  |  | 157 |
Accumulated depreciation and amortization | (575) |  |  | (359) |
Property and equipment, net | $ | 611 |  |  | $ | 720 |
Depreciation and amortization expenses of $216 and $206 for the years ended December 31, 2025 and 2024, respectively, were recorded within costs of revenue and components of operating expenses. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities comprised the following:
| December 31, 2025 |  | December 31, 2024
Accrued compensation | $ | 568 |  |  | $ | 349 |
Accrued clinical trial expenses | 83 |  |  | 13 |
Accrued R&D expenses | 1,448 |  |  | — |
Accrued sales taxes | 79 |  |  | 67 |
Other | 519 |  |  | 140 |
Accrued expenses and other current liabilities | $ | 2,697 |  |  | $ | 569 |

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration